NOVAVAX INC Acquisitions, Net of Cash Acquired
NOVAVAX INC (NVAX) reported Acquisitions, Net of Cash Acquired of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2023-02-28
- NOVAVAX INC payments to acquire businesses, net of cash acquired for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- NOVAVAX INC payments to acquire businesses, net of cash acquired for the quarter ending 2021-09-30 was $0.00.
- NOVAVAX INC payments to acquire businesses, net of cash acquired for the quarter ending 2020-12-31 was $1.31M.
- NOVAVAX INC payments to acquire businesses, net of cash acquired for the quarter ending 2020-09-30 was $0.00.
- NOVAVAX INC payments to acquire businesses, net of cash acquired for fiscal 2022 was $0.00.
- NOVAVAX INC payments to acquire businesses, net of cash acquired for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- NOVAVAX INC payments to acquire businesses, net of cash acquired for fiscal 2020 was $165.52M.
- NOVAVAX INC payments to acquire businesses, net of cash acquired for fiscal 2019 was $0.00.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 | |||
| 2020-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.31M derived: sum of 2 quarters · filed 2023-02-28 | $165.52M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $164.20M 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | $164.20M 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 | |||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |